Profound Medical Corp. (NASDAQ:PROF) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Dr. Arun Menawat – Chief Executive Officer and Chairman of the Board Rashed Dewan – Chief Financial Officer Stephen Kilmer – Investor Relations Conference Call Participants Rahul Sarugaser – Raymond James Frank Takkinen – Lake Street Capital Markets Josh Jeggings – Cowen and Company Scott McAuley – Paradigm Capital Brian Gagnon – Gagnon Securities Operator Good day, and thank you for standing by ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2021 Results Conference Call March 3, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Rahul Sarugaser - Raymond James Josh Jennings - Cowen Frank Takkinen - Lake Street Capital Brian Gagnon - Gagnon Securities Ben Haynor - Alliance Global Partners Operator Hello. Thank you for standing by. Welcome to the Profound Medical Q4 and Full Year 2021 Financial Results Conference Call. At this time ...

EXHIBIT 99.1 Profound Medical Announces Fourth Quarter and Full Year 2021 Financial Results TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2021. Unless specified otherwise, all amounts in this press release ...

Financial Data and Key Metrics Changes - For Q3 2021, the company recorded revenue of $2.5 million, up 13% from $2.2 million in Q3 2020 [13] - Total operating expenses increased by 30% to $8.6 million compared to approximately $6.6 million in Q3 2020 [13] - The net loss for Q3 2021 was $6 million or $0.29 per share, compared to a net loss of $6.1 million or $0.33 per share in the same period of 2020 [15] Business Line Data and Key Metrics Changes - R&D expenses increased by 14% year-over-year to $4 million, driven by costs associated with clinical trials and MRI utilization [14] - G&A expenses rose by 35% to $2.5 million due to employee options and increased insurance costs [15] - Selling and distribution expenses surged by 72% to approximately $2 million [15] Market Data and Key Metrics Changes - TULSA-PRO procedure volumes in the U.S. grew 20% sequentially from Q2 to Q3 2021, indicating a developing trend [17] - The company expects to have approximately 20 U.S. installed sites by year-end, down from a previous estimate of 25 due to COVID-related delays [22] Company Strategy and Development Direction - The company is focusing on building a high-quality U.S. installed base by targeting early adopters, independent imaging centers, and leading teaching hospitals [19] - The strategy includes optimizing the onboarding process to reduce installation times post-pandemic [23] - The company is progressing with its reimbursement strategy, planning to file for a CPT code application in 2022 [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term growth potential despite COVID-related challenges, citing strong utilization trends [18] - The company anticipates that delays in installations will diminish by year-end, allowing for a more robust growth trajectory in 2022 [23] - Management highlighted the importance of clinical data in supporting reimbursement applications and driving adoption [30] Other Important Information - The company has received FDA approval under Humanitarian Device Exemption for the treatment of osteoid osteoma, marking a significant milestone [8] - The interim results of a European trial showed superior outcomes for TULSA-PRO compared to traditional robotic prostatectomy [26] Q&A Session Summary Question: Update on the TACT trial - The TACT trial is nearing completion, with a few patients left to enroll, and three-year data shows continued improvement in side effects [34] Question: Install base expectations - There has been no dropout from the install base, and utilization continues to increase despite delays [39] Question: Impact of staffing shortages on procedure volumes - Staffing shortages have affected large hospitals, but the company has still seen significant growth in procedure volumes [41] Question: Capacity for installations in 2022 - The company has sufficient personnel to install devices rapidly, but hospital capacity remains a bottleneck [46] Question: Reimbursement timelines - The company plans to file for CPT-1 application next year, with all necessary clinical publications expected by the end of this year [50] Question: Trends in BPH versus cancer patients - The majority of patients treated are prostate cancer patients, with plans to broaden the scope for BPH applications in the future [92]

Profound Medical Corp. (NASDAQ:PROF) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Dr. Arun Menawat - Chief Executive Officer Aaron Davidson - Senior Vice President, Corporate Development Conference Call Participants Rahul Sarugaser - Raymond James Neil Chatterji - Cowen Anthony Petrone - Jefferies Frank Takkinen - Lake Street Capital Markets Ben Haynor - Alliance Global Partners Scott McAuley - Paradigm Capital Operator Good day and than ...

Profound Medical Corp. (NASDAQ:PROF) Q1 2021 Earnings Conference Call May 12, 2021 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Aaron Davidson – Senior Vice President-Corporate Development and Chief Financial Officer Arun Menawat – Chief Executive Officer Conference Call Participants Brianna O'Toole – Jefferies Rahul Sarugaser – Raymond James Josh Jennings – Cowen Frank Takkinen – Lake Street Capital Ben Haynor – Alliance Global Partners Operator Thank you for standing by and welcome ...

Financial Data and Key Metrics Changes - For Q4 2020, the company recorded revenue of $2.9 million, a 36% increase year-over-year and a 29% increase sequentially from Q3 2020 [14] - Total operating expenses were $6.1 million, up 14% from approximately $5.3 million in Q4 2019 [15] - The net loss for Q4 2020 was $7.5 million or $0.38 per share, compared to a net loss of $3.9 million or $0.33 per share in Q4 2019 [19] Business Line Data and Key Metrics Changes - R&D expenses increased by 4% to $2.5 million, driven by higher spending on clinical trials and employee-related costs [16] - Selling and distribution expenses surged by 79% to approximately $1.7 million, reflecting increased investment in the commercialization of TULSA-PRO [18] Market Data and Key Metrics Changes - The company has successfully established TULSA-PRO in the U.S. market, with early adopters achieving an average run rate of 60 procedures per year, exceeding initial expectations by about 50% [25] - RadNet has begun treating patients using TULSA-PRO after initial COVID-19 related delays [26] Company Strategy and Development Direction - The company aims to build a high-quality U.S. installed base for TULSA-PRO, targeting early adopters, independent imaging centers, and opinion-leading teaching hospitals [23] - The company is focused on reimbursement strategies, having submitted an application for a healthcare common procedure coding system C code from CMS for TULSA-PRO [28] Management's Comments on Operating Environment and Future Outlook - Management remains cautious about near-term performance due to unpredictable COVID-19 impacts but is optimistic about long-term adoption goals for TULSA-PRO [32] - The company plans to launch Sonalleve in the U.S. later in 2021, following its humanitarian device exemption approval [9][32] Other Important Information - The company has changed its presentation currency from Canadian dollars to U.S. dollars to better reflect its operations [13] - As of December 31, 2020, the company had cash reserves of $83.9 million [19] Q&A Session Summary Question: Can you provide insights on the average installation cycle pre-COVID and its current status? - The average installation cycle is currently between 75 to 90 days, with expectations to reduce to 45 to 60 days in the long term [36] Question: Are all existing contracts installed, or are there more contracts being signed? - There are contracts signed that have not yet been installed, and new contracts are being signed this year [44] Question: What is the reimbursement level under the C code? - The reimbursement generally ranges from $11,000 to $12,500, depending on the type of institution [39] Question: What progress is being made in international markets, particularly Japan and Europe? - Japan is expected to be an important market, with new orders being received, while Europe is seeing increased interest and additional clinical trials [54][56] Question: How does the recent study on MRI for prostate cancer diagnosis impact TULSA-PRO adoption? - The study indicates a potential increase in MRI use for diagnosis, which could positively influence TULSA-PRO adoption [58] Question: What are the expectations for installations and utilization moving forward? - The company has a strong pipeline and anticipates continued growth in installations and utilization, with a target of over 100 procedures in the long term [66][68]

Profound Medical Corp. (NASDAQ:PROF) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Arun Menawat - Chief Executive Officer Aaron Davidson - Chief Financial Officer and Senior Vice President, Corporate Development Conference Call Participants Raj Denhoy - Jefferies Frank Takkinen - Lake Street Capital Operator Good day, ladies and gentlemen and welcome to the Profound Medical Third Quarter 2020 Financial Results Conference Call and Webcas ...

Profound Medical Corp. (NASDAQ:PROF) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Arun Menawat - Chief Executive Officer Aaron Davidson - Chief Financial Officer & Senior Vice President of Corporate Development Conference Call Participants Josh Jennings - Cowen Rahul Sarugaser - Raymond James Ben Haynor - Alliance Global Partners Operator Good day, ladies and gentlemen, and welcome to your Profound Medical Second Quarter 2020 Financial R ...

Profound Medical Corp. (NASDAQ:PROF) Q1 2020 Results Conference Call May 7, 2020 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Aaron Davidson - CFO and SVP, Corporate Development Conference Call Participants Josh Jennings - Cowen and Company Rahul Sarugaser - Raymond James Brian Gagnon - Gagnon Securities Operator Greetings, and welcome to the Profound Medical First Quarter 2020 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being re ...